
News & Insights
This is where we share our own and our portfolio companies’ press releases as well as relevant Sunstone articles, analyses and SoMe posts.
5 latest press releases
5 latest articles
News Archive
Orphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic Lateral Sclerosis
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announces that the Company has received Fast Track Designation from the US Food and Drug Administration (FDA) for the...
VAXIMM Announces Results from VXM01 Phase I/II Combination Trial with PD-L1 Inhibitor Avelumab to be Presented at ASCO20
14 May 2020, VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the safety run-in results from a Phase I/II study in progressive glioblastoma with its lead product candidate, oral VXM01, in combination...
Patent for Oncoral approved in Japan
Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia”) today announced that the patent application for Oncoral has been approved in Japan. The approval in Japan adds to the already obtained patents in the US and a selected number of countries in Europe and China. The...
Susanne Rydberg utses till ny VD för Arcoma AB
Styrelsen i Arcoma har utsett Susanne Rydberg till ny Verkställande Direktör. Susanne Rydberg har lång erfarenhet från ledande positioner, senast nu som VD för Eurofins BioPharma Product Testing Sweden AB och dessförinnan som verksamhetschef för Lindes Nordeuropeiska...
Sunstone announce new investment in immuno-oncology company STipe Therapeutics
Sunstone Life Science Ventures today announce it has invested in new portfolio company Stipe Therapeutics ApS (“STipe”), an immuno-oncology company dedicated to developing novel cancer therapeutics based on its first class drugs modulating the STING pathway.
Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia
Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces positive results in the pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia...
Sunstone makes €5 million investment into Finnish women’s health company Forendo Pharma to finance clinical studies in endometriosis
Sunstone Life Science Ventures today announced its first investment out of its Life Science Ventures Fund IV into Forendo Pharma, a Finnish clinical stage drug development company focusing on novel treatments in women’s health. The investment is designated to finance...
Sunstone makes a non-revocable commitment to sell all shares in Nuevolution at a price of SEK 32.5 per share to Amgen, corresponding to SEK 332 million
Sunstone today announced that its Life Science Ventures Fund I has made a non-revocable commitment to sell all shares in Nuevolution AB at a price of SEK 32.5 per share. Nuevolution has been part of Sunstone’s portfolio since 2007 and Sunstone has played an active...
Trading in Ascelia Pharma’s shares on Nasdaq Stockholm commences tomorrow
Nasdaq Stockholm AB has today decided to admit the shares of Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) for trading on Nasdaq Stockholm with first day of trading tomorrow, Wednesday 13 March 2019. The shares will be traded under the ticker ACE and ISIN...
Articles Archive
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.